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Abstract: In this study we evaluate the suitability of two methods of RNA conservation in blood samples, PAXgene and RNAlater, 
in combination with variable shipping conditions for their application in multicenter studies and biobanking. RNA yield, integrity, 
and purity as well as levels of selected mRNA and microRNA species were analyzed in peripheral human blood samples stabilized by 
PAXgene or RNAlater and shipped on dry ice or at ambient temperatures from the study centers to the central analysis laboratory. Both 
examined systems were clearly appropriate for RNA stabilization in human blood independently of the shipping conditions. The isolated 
RNA is characterized by good quantity and quality and well suited for downstream applications like quantitative RT-PCR analysis of 
mRNA and microRNA. Superior yield and integrity values were received using RNAlater. It would be reasonable to consider the pro-
duction and approval of blood collection tubes prefilled with RNAlater to facilitate the use of this excellent RNA stabilization system 
in large studies.
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A major aim in cancer research is the   identification 
and  validation  of  appropriate  tumor  markers 
  detectable in easily accessible body fluids. Human 
blood  is  a    preferred  source  of  markers  due  to  the 
  minimal invasive character of sample collection and 
the   vascularization of most tissues (including tumors). 
For marker discovery the analysis of mRNA expres-
sion signatures in peripheral human blood has been 
widely used showing to be a promising technique.1 
Once  markers  with  potential  diagnostic  relevance 
are identified they need to be validated in large pro-
spective studies, commonly conducted in multicenter 
studies. The different participating study centers are 
usually separated by varying distances from a   central 
analysis  laboratory  or  biobank.  Study  centers  face 
the challenge of having limited access to research 
  laboratory support and might be unable to perform 
RNA isolation immediately after blood collection.2 
Additionally,  isolation  and  analysis  of  RNA  in  a 
central laboratory avoid inter-laboratory variations.3 
Such a study design results in unique challenges due 
to pre-analytical variations occurring before marker 
analyses and includes factors like method of blood 
collection,  shipping  conditions,  and  time  delay 
between sample collection and analysis.4 RNA sta-
bility plays a crucial role due to pre-analytical varia-
tions, especially degradation by endogenous RNases 
and unintentional expression of individual genes after 
blood drawing.5 Altered expression signatures based 
on pre-analytical variations lead to false assessments 
of potential markers. Therefore, evaluation of influ-
ences  on  marker  integrity  and  standardization  of 
sample collection, shipping, and storage conditions in 
biobanking is necessary to ensure reliable and repro-
ducible analyses of markers.2
Discovery of microRNAs (miRNAs) has opened 
new opportunities for markers in the diagnosis of can-
cer.6 MiRNAs are small (18–26 nucleotides) noncod-
ing RNAs playing a central role in the regulation of 
gene expression.7 Altered miRNA expression has been 
reported in several human malignancies and differences 
between tumor tissues and their normal counterparts 
could be exploited for diagnostics and prognosis.8
The introduction of blood collection systems con-
taining stabilizing additives has significantly improved 
the  RNA  quantity  and  quality  of  blood  samples 
  collected in multicenter studies.9,10 RNA   stabilization 
systems have the advantage that there is no need to 
isolate the RNA immediately. Instead, the collected 
blood samples can be stored at more   accessible tem-
peratures in the study centers before shipment to the 
central  analysis  laboratory  or  biobank  resulting  in 
reduced pre-analytical variability. A well-  described 
method for RNA stabilization in human blood is the 
PAXgene  system.9,11–13  In  contrast  to  mRNAs  less 
is known about the ability of PAXgene to stabilize 
miRNAs in peripheral blood samples. Recently, it has 
been reported that miRNAs could be isolated from 
PAXgene-stabilized blood and that quantity and qual-
ity might be sufficient for downstream applications.14 
However,  failure  of  PAXgene  to  stabilize  specific 
transcripts was also reported.15 Therefore,   alternative 
methods for RNA stabilization in blood need to be 
evaluated.  RNAlater  is  a  common  stabilization 
reagent  for  RNA  in  cells  and  tissues  increasingly 
being used in genomic studies and biobanking.16 To 
our   knowledge, no study analyzing the usability of 
RNAlater for RNA stabilization in human peripheral 
blood was conducted so far.
The  aim  of  our  study  was  to  evaluate  the 
  performance  of  PAXgene  and  RNAlater  for  RNA 
stabilization in peripheral blood and the influences of 
shipping conditions and subsequent storage on RNA 
yield, integrity, purity, and amount of specific mRNA 
and miRNA species.
Material and Methods
Sample collection and shipping 
conditions
In March and April 2009 peripheral blood samples from 
43 male former uranium miners (mean age 78 years, 
range  76–89  years)  exposed  to  radon  and  other  car-
cinogens  were  collected  in  three  participating  study 
centers. As study centers served local medical offices 
assigned to exammine former uranium miners in Sch-
neeberg, Plauen, and Niederdorf in Thuringia, Germany. 
All volunteers provided written informed consent and 
permission was obtained from the ethics committee of 
the Bavarian Chamber of Physicians (reference number 
08082).
The workflow of the study design is presented in 
Figure 1. In brief, from each donor peripheral blood 
was collected in a 9.0 ml EDTA vacutainer (Becton 
Dickinson, Heidelberg, Germany) and three 2.5 ml 
PAXgene  Blood  RNA  vacutainers  (PreAnalytiX, 
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Figure 1. Workflow of the study design.
Hombechtikon, Switzerland). Aliquots (0.5 ml each) 
of EDTA blood were mixed with 1.3 ml RNAlater 
(Ambion, Austin, TX, USA) immediately after blood 
drawing. Until shipment, two blood+RNAlater   aliquots 
(RNAlater/frozen, RNAlater/frozen+stored) and two 
PAXgene  vacutainers  (PAXgene/frozen,    PAXgene/
frozen+stored)  were  stored  on  dry  ice17  and  the 
remaining PAXgene vacutainer (PAXgene/  ambient) 
and  blood+RNAlater  aliquot  (  RNAlater/ambient) 
were  stored  at  ambient  temperature.    Shipment  of 
blood samples from the study centers to the central 
analysis  laboratory  was  performed  frozen  on  dry 
ice by courier service over night (  PAXgene/frozen, 
  PAXgene/frozen+stored, RNAlater/frozen,   RNAlater/
frozen+stored) and at ambient temperatures by regu-
lar mail with possible delay in   delivery (  PAXgene/
ambient,  RNAlater/ambient).  After  arrival  at  the 
central  analysis  laboratory    PAXgene/frozen+stored 
and  RNAlater/frozen+stored  samples  were  stored 
at -80 °C for six months until processing. All other 
blood samples were processed immediately.
RnA Isolation
Frozen samples were thawed at room temperature and 
RNA was isolated immediately after thawing using the 
PAXgene Blood RNA Kit (Qiagen, Hilden,   Germany) 
for the PAXgene samples and the RiboPure Blood Kit 
(Ambion) for the RNAlater samples. RNA was iso-
lated according to the manufacturers’   instructions and 
stored in elution buffers supplied with the isolation 
kits at -80 °C until analysis.
RnA Yield, purity, and Integrity
Concentration  and  purity  of  RNA  were  quantified 
by measuring the absorbance at 260 nm (A260) and 
280 nm (A280) using a NanoDrop ND-100 spectro-
photometer (Thermo Scientific, Waltham, MA, USA). 
RNA yields were calculated from RNA   concentrations 
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shipping conditions, and subsequent storage.
n RnA yield 
(μg/ml blood)
RnA integrity 
(RIn)
RnA purity 
(A260/A280)
Median IQR Median IQR Median IQR
PAXgene/frozen 41 1.6 0.8–2.1 7.4 4.2–8.3 2.08 2.04–2.13
RnAlater/frozen 43 7.5 5.0–9.3 8.5 8.1–9.1 1.95 1.89–2.02
PAXgene/ambient 43 1.4 0.8–2.1 6.9* 5.4–7.8* 2.06 1.96–2.10
RnAlater/ambient 43 4.4 2.7–6.2 8.2 7.7–8.7 1.99 1.87–2.16
PAXgene/frozen+stored 41 2.2 1.5–3.0 7.8 7.4–8.3 2.08 2.04–2.12
RnAlater/frozen+stored 43 6.2 5.0–8.4 8.6 8.1–9.0 1.92 1.84–2.04
note: *n = 42 (Determination of RIn failed in one sample).
relative  to  one  milliliter  of  blood.  Qualitative 
  analyses of RNA were performed with the Agilent 
2100   Bioanalyzer using RNA 6000 Nano and RNA 
6000 Pico assays (Agilent Technologies, Santa Clara, 
CA, USA) according to manufacturer’s   instructions. 
The  Bioanalyzer  system  is  based  on    capillary 
  electrophoresis, which has become an established and 
common tool18 allowing separation with high resolu-
tion as well as quantification with high accuracy19 
and is therefore suitable for reliable quality control of 
RNA.20 According to Schroeder et al RNA integrity 
numbers (RIN) from 0–10 (low to high RNA quality) 
were calculated using the Agilent software.21
Quantitative Real Time-pcR  
(qRT-pcR)
The  ATM  gene  (ataxia-telangiectasia  mutated)  was 
selected  as  target  because  altered  expression  was 
observed after exposure to ionizing radiation.22 RNA 
was analyzed using the TaqMan reverse transcription 
reagents and the TaqMan gene expression assays for 
ATM (order number Hs00175892) and GAPDH (order 
number Hs99999905) according to the manufacturer’s 
instructions. All primers and reagents were obtained 
from Applied  Biosystems  (Foster  City,  CA,  USA). 
For cDNA synthesis samples were incubated at 42 °C 
for 80 min followed by an incubation at 95 °C for 
5 min. Using the miRGen database23 miRNA-26a and 
  miRNA-26b were determined as possible regulators due 
to their potential binding capacity to the ATM mRNA. 
MiRNAs were analyzed using the   commercial Taq-
Man microRNA assays for miRNA-26a (order number 
4373070) and miRNA-26b (order number 4373069) 
obtained from Applied Biosystems and performed as 
described previously.24 For cDNA synthesis samples 
were incubated at 16 °C for 30 min, 42 °C for 30 min, 
and at 85 °C for 5 min. Quantitative real time-PCR 
(qRT-PCR) was performed using a MJ Research PTC-
200 thermal cycler (Global Medical Instrumentation, 
Inc., Ramsey, MN, USA) and an Applied Biosystems 
7300 Real-Time PCR System (Applied Biosystems). 
Samples were initially denatured at 95 °C for 10 min, 
followed by 40 sequential cycles at 95 °C for 15 sec 
and at 60 °C for 1 min. Non-template controls were 
included in all assays. Raw Ct values of all samples are 
listed in Supplementary Table 1.
The cycle threshold (Ct) is defined as the num-
ber of cycles required for the FAM signal to cross 
the threshold in qRT-PCR. For Ct estimation a fixed 
threshold of 0.2 was used.25 Targets with Ct . 35 
are considered to be under the detection limit26 and 
marked as 35 for calculation.27 Samples were analyzed 
in duplicate and ratios of ATM mRNA, miRNA-26a, 
and miRNA-26b to GAPDH mRNA were calculated 
using mean Ct values.
statistical Analysis
Median values and inter-quartile ranges (IQR) were 
calculated for RNA yield, purity, and integrity strati-
fied by stabilization systems and shipping conditions. 
Differences  between  the  paired  observations  were 
determined by Wilcoxon signed-rank test. A repeated 
measurement analysis of variance (ANOVA) of sta-
bilization  system  and  shipping  conditions  as  main 
effects and their interaction was performed with ranks 
for RNA yield, integrity, and Ct values. P-  values were 
adjusted  for  multiple  testing  by  Bonferroni-Holm   
correction.
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Sample collection and shipment
From 258 anticipated blood samples of 43 partici-
pants  (six  per  donor)  two  samples  for  PAXgene/
frozen+stored  could  not  be  drawn.  All  samples 
shipped  by  courier  service  from  the  participating 
study centers to the central analysis laboratory were 
delivered on the next day without any delay. Five 
PAXgene/  ambient and five RNAlater/ambient sam-
ples shipped by regular mail arrived with a delay of 
four days whereas all other samples shipped by mail 
(N = 38) were delivered not later than two days after 
sending.
RnA Recovery
RNA could be isolated from 254 of 256   delivered blood 
samples,  including  all  RNAlater/frozen,    RNAlater/
ambient, RNAlater/frozen+stored, PAXgene/  ambient, 
and  PAXgene/frozen+stored  samples.  Isolation  of 
two PAXgene/frozen samples failed due to imperfect 
  filling of the vacutainers.
Median  values  and  IQR  of  RNA  yield,  integ-
rity,  and  purity  subjected  to  stabilization  system, 
shipping  conditions,  and  subsequent  storage  are 
presented  in  Table  1.  Highest  yield  (7.5  µg/ml 
blood, IQR 5.0–9.3 µg/ml blood) was observed in   
RNAlater/frozen samples and lowest yield (1.4 µg/
ml  blood,  IQR  0.8–2.1  µg/ml  blood)  in  PAX-
gene/ambient   samples. Highest RIN value was 8.6   
(IQR  8.1–9.0)  for    RNAlater/frozen+stored  sam-
ples and   lowest RIN value was 6.9 (IQR 5.4–7.8) 
for  PAXgene/  ambient  samples.  Median  purity  of 
the isolated RNA ranged from 1.92 for RNAlater/
frozen+stored (IQR 1.84–2.04) to 2.08 for PAXgene/
frozen and PAXgene/frozen + stored (IQR 2.04–2.13 
and 2.04–2.12, respectively).
Significant influence of the stabilization   systems on 
RNA yield and integrity was demonstrated, whereas 
shipping conditions had a significant impact on yield 
only. No clear interaction of stabilization systems and 
shipping conditions could be found. Overall, higher 
yields and RIN values were observed in RNAlater-
stabilized samples compared to PAXgene-stabilized 
samples independent of shipping conditions or stor-
age (P , 0.0001). Frozen shipping of RNAlater sam-
ples resulted in higher yield compared to shipping at 
ambient temperature (7.5 vs. 4.4 µg/ml; P , 0.0001). 
Using PAXgene a higher average yield was achieved 
for frozen+stored samples in comparison to frozen 
samples (2.2 vs. 1.6 µg/L; P = 0.0002).
Median values and IQR of RNA yield, integrity, 
and purity of samples shipped at ambient tempera-
tures due to different delivery times are presented in 
Table 2. Differences could not be evaluated because 
of the small number of samples.
RnA Analyses
Amounts  of  ATM  mRNA  were  not  influenced  by 
  stabilization system or shipping conditions, whereas for 
miRNA-26a and miRNA-26b a significant impact of the 
stabilization  systems  was  observed.  The  interaction 
of stabilization systems and   shipping conditions had a 
significant  impact  only  for  miRNA-26b.  ATM 
mRNA  amounts  were  altered  between 
  RNAlater/  frozen and RNAlater/frozen+stored samples 
(P , 0.0001) (Fig. 2A). Different amounts of   miRNA-26a 
were  revealed  for  PAXgene/frozen  vs. 
RNAlater/  frozen (P , 0.0001), PAXgene/  ambient vs. 
RNAlater/ambient  (P  ,  0.0001),  PAXgene/frozen 
vs.    PAXgene/frozen+stored  (P  ,  0.0001),  PAXgene/
frozen+stored vs. RNAlater/frozen+stored (P < 0.0001), 
and  RNAlater/  frozen  vs.  RNAlater/frozen+stored 
Table 2. Median values and inter-quartile ranges (IQR) of RnA yield, integrity, and purity of PAXgene- and RnA   later-  stabilized 
blood samples shipped at ambient temperature by regular mail and with different delivery times.
sample Delivery time n RnA yield (μg/ml blood) RnA integrity (RIn) RnA purity (A260/A280)
Median IQR Median IQR Median IQR
PAXgene 1–2 days 38 1.6 0.8–2.1 7.3* 5.6–7.8* 2.01 1.96–2.09
4 days 5 1.2 0.9–1.2 6.1 5.4–6.5 2.11 2.07–2.11
RnAlater 1–2 days 38 4.4 2.6–6.2 8.2 7.7–8.7 2.01 1.90–2.17
  4 days 5 4.6 4.2–5.9 8.5 8.4–8.6 1.84 1.80–1.87
note: *n = 37 (Determination of RIn failed in one sample).
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(data not shown).
Discussion
A  crucial  challenge  of  gene  expression  analy-
ses for marker discovery is sample handling after 
blood collection when immediate RNA isolation is 
not   possible.2 For multicenter studies with blood-
based samples the choice of stabilization systems 
and   shipping conditions is important because RNA 
degrades time-dependently during sample shipment 
to the central analysis laboratory.28 Additionally, suf-
ficient sample integrity during short-term and long-
term storage in biobanks should be warranted.
We  analyzed  two  systems  regarding  their  per-
formance to stabilize mRNA and miRNA in human 
peripheral blood and the influence of sample ship-
ment under frozen conditions per courier service and 
at ambient temperatures by regular mail, with and 
without additional delay in delivery.
The  obtained  RNA  yields  in  RNAlater-stabilized 
samples are consistently higher than in PAXgene-stabi-
lized samples. Discrepancies might be due to suscepti-
bility of PAXgene to an imperfect ratio of stabilization 
reagent to blood caused by insufficient filling of the 
vacutainers. Disparities result in poor RNA isolation or 
even in failed RNA isolation as happened in two cases 
during this study. A simple strategy to check the filling 
degree of the PAXgene vacutainers can be weighing. 
PAXgene  vacutainers  filled  completely  with  2.5  ml 
blood have a weight of 19.35 g and for successful RNA 
isolation a tolerance range of ±0.5 g might be acceptable 
(personal communication T. Voss, Qiagen, Germany). 
However, when strictly adhering to the manufacturers’ 
protocols both stabilization systems provide sufficient 
RNA yields for downstream applications.
Analysis of RNA integrity and purity served as 
tool to determine the overall quality of stabilization, 
preparation, and purification that can be influenced 
by  degradation.3  Regarding  purity,  ratios  .1.8  are 
considered suitable for gene expression analyses.20 
Good RNA purities were obtained throughout for all 
stabilization systems, shipping conditions, and subse-
quent storage, reflecting efficient isolation and purifi-
cation procedures. For RNA quality it was suggested 
that RIN values should be at least .5 and values .8 
are perfect for downstream applications.18,29 Samples 
  stabilized with RNAlater provided an average   integrity 
(P , 0.0001), (Fig. 2B). For miRNA-26b altered amounts 
were observed for   PAXgene/frozen vs. PAXgene/  ambient 
(P  ,  0.0001),  PAXgene/frozen  vs.  RNAlater/  frozen 
(P  ,  0.0001),  and  PAXgene/frozen+stored  vs. 
RNAlater/frozen+ stored (P , 0.0001), (Fig. 2C).
Differences of ATM mRNA, miR-26a, and   miR-26b 
amounts due to different delivery times could not be 
Figure 2. normalized levels of ATM (A), miRnA-26a (B), and   miRnA-26b 
(c) depending on stabilization systems, shipping conditions, and subse-
quent storage.
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values. Based on the obtained results   isolated RNA 
stabilized by either PAXgene or RNAlater is highly 
appropriate for qRT-PCR.
While the quality of RNA differed by stabilization 
system, no differences of ATM mRNA levels could be 
observed in RNAlater and PAXgene stabilized blood 
samples shipped frozen or at ambient temperatures, 
indicating that both systems and shipping conditions 
are highly feasible for stabilization of mRNA. How-
ever, it was reported that PAXgene failed to stabilize 
certain transcripts.15 Therefore, before starting mul-
ticenter studies it will be meaningful to analyze the 
intended stabilization system under the selected ship-
ping condition with the transcripts of interest. Because 
only one mRNA species was analyzed in our study, a 
failed stabilization of other mRNAs by RNAlater or 
PAXgene cannot be ruled out. Surprisingly, despite 
a  general  excellent  stability  of  miRNAs  in  human 
blood30 miRNA-26a and miRNA-26b appeared to be 
more susceptible to stabilization systems and shipping 
conditions, similar to the failed stabilization of certain 
mRNAs observed by Kagedal et al.15 Indeed, it was 
demonstrated recently that individual miRNAs possess 
different stabilities31 while little is known about the 
specific stabilities of miRNA-26a and miRNA-26b. In 
this context it should be noted that the isolation proce-
dures used in this study were not specifically adapted 
for miRNAs. Therefore, some variations of miRNA 
levels might be due to shortcomings of the isolation 
procedures.  Also,  because  different  RNA  isolation 
procedures  were  used,  the  differences  between  the 
two stabilization systems might be due, in part, to the 
different RNA kits. Meanwhile, optimized isolation 
protocols for PAXgene and RNAlater became avail-
able that have the potential to enhance the recovery 
rates of miRNAs in the stabilized samples. Recently, 
Gaartz et al successfully used a specific miRNA isola-
tion kit for PAXgene-stabilized blood samples.32
Our results clearly indicate that both stabilization 
systems are well suited for the application in mul-
ticenter  studies.  Particularly,  shipping  of  collected 
samples by regular mail at ambient temperatures is 
simple, saves cost, and greatly reduces the workload 
for participating study centers that are usually not 
accustomed to perform scientific studies. Based on 
our results the use of PAXgene or RNAlater facili-
tates  the  stabilization  of  RNA  for  several  days  at 
ambient temperatures without consistent alterations 
in yield, integrity, and purity of total RNA and levels 
of   individual mRNA and miRNA species.
Regarding  the  storage  of  samples  in  biobanks, 
both stabilization systems seem to be suitable at least 
for short-term storage (up to six months) as indicated 
by  the  results  of  this  study.  Regarding  long-term 
storage PAXgene samples could be stored for up to 
50 months at -80 °C without any alterations in RNA 
levels according to the manufacturers’ protocol. For 
long-term storage of RNAlater-stabilized blood sam-
ples nothing is known yet.
With regard to the handling in fieldwork, the use 
of PAXgene is favorable because the staff in study 
centers does not need experience in sample process-
ing.  As  blood-collection  systems  already  prefilled 
with RNAlater are not available yet, the blood col-
lecting tubes need to be opened to mix the blood with 
RNAlater. Besides requiring technical expertise this 
additional step possesses a potential risk of infection. 
Based on the good performance of RNAlater to stabi-
lize RNA in human peripheral blood, the production 
and approval of blood collection tubes prefilled with 
RNAlater would support the use of this excellent iso-
lation system in large studies.
In conclusion, our study shows that PAXgene and 
RNAlater were both appropriate for RNA stabilization 
in  blood  independently  of  the  shipping  conditions. 
Both systems facilitate the isolation of stabilized RNA 
from blood, which is characterized by good quantity 
and quality and is well suited for qRT-PCR of mRNA 
and miRNA. To our knowledge, this is the first study 
investigating the use of RNAlater for stabilization of 
RNA in human peripheral blood. It could be shown that 
RNAlater performs well and constitutes an alternative 
to existing systems, provided that a user-friendly han-
dling, by i.e. prefilled collection tubes, will be possible 
in the future. However, evaluation of a large panel of 
mRNAs and miRNAs is necessary to validate RNAl-
ater for the use of RNA stabilization in blood.
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